ABVC BioPharma, Inc. (ABVC)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
ABVC Insider Trading Activity
ABVC Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Insider Activity of ABVC BioPharma, Inc.
Over the last 12 months, insiders at ABVC BioPharma, Inc. have bought $0 and sold $0 worth of ABVC BioPharma, Inc. stock.
On average, over the past 5 years, insiders at ABVC BioPharma, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $1,500 was made by Nirta Joseph (director) on 2010‑05‑11.
List of Insider Buy and Sell Transactions, ABVC BioPharma, Inc.
| 2010-05-11 | Nirta Joseph | director | 10,000 0.0305% | $0.15 | $1,500 | |||
| 2010-03-22 | Nirta Joseph | director | 2,000 0.0061% | $0.26 | $520 | |||
| 2009-10-01 | Stromback Richard Dean | 10 percent owner | 240 – | $0.42 | $101 | |||
| 2009-04-14 | Smith J.B. | 21 <0.0001% | $0.75 | $16 | ||||
| 2009-01-23 | Sale | Stromback Richard Dean | 4M 13.8448% | $1.00 | $4M | |||
| 2009-01-23 | Smith J.B. | 4M 13.8448% | $1.00 | $4M | ||||
| 2008-08-18 | Sale | Stromback Richard Dean | CEO | 1.5M 0.3123% | $1.00 | $1.5M | ||
| 2007-07-30 | Ramsey Sally Judith | VP New Product Development | 3M – | $0 | $0 |
ABVC Institutional Investors: Active Positions
| Increased Positions | 9 | +150% | 181,195 | +79.4% |
| Decreased Positions | <1 | -16.67% | 60 | -0.03% |
| New Positions | 4 | New | 57,350 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 14 | +133.33% | 409,327 | +79.38% |
ABVC Ownership Change vs Market
Institutional Investor Ownership
| Avantax Planning Partners, Inc. | $93.00 | 1.11% | 143,968 | +104,968 | +269.15% | 2024-12-31 |
| Geode Capital Management, Llc | $51.00 | 0.61% | 79,285 | +7,678 | +10.72% | 2024-12-31 |
| Vanguard Group Inc | $30.00 | 0.36% | 46,947 | 0 | 0% | 2024-12-31 |
| Citadel Advisors Llc | $26.00 | 0.31% | 40,743 | +40,743 | New | 2024-12-31 |
| Xtx Topco Ltd | $22.00 | 0.27% | 34,405 | +11,000 | +47% | 2024-12-31 |
| Northern Trust Corp | $12.00 | 0.15% | 19,135 | 0 | 0% | 2024-12-31 |
| Virtu Financial Llc | $10.00 | 0.12% | 15,935 | +15,935 | New | 2024-12-31 |
| State Street Corp | $8.00 | 0.1% | 12,900 | 0 | 0% | 2024-12-31 |
| Two Sigma Securities, Llc | $8.00 | 0.1% | 12,593 | +196 | +1.58% | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $2.00 | 0.02% | 2,563 | -60 | -2.29% | 2024-12-31 |